Evidence map›Paper›PMID 30598509›Full record

ArticleThe Journal of biological chemistry2019

A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor α agonists.

Rahul Patil, Biswaranjan Mohanty, Bonan Liu, Indu R Chandrashekaran, Stephen J Headey, Martin L Williams, Craig S Clements, Olga Ilyichova, Bradley C Doak, Patrick Genissel and 5 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Monounsaturated Fatty Acids in Obesity-Related Inflammation.International journal of molecular sciences · 2020
    Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 5 countries.

Rahul PatilFrom Medicinal Chemistry.
Biswaranjan MohantyFrom Medicinal Chemistry.ORCID 0000-0002-6921-343X
Bonan LiuDrug Delivery, Disposition and Dynamics, and.
Indu R ChandrashekaranFrom Medicinal Chemistry.
Stephen J HeadeyFrom Medicinal Chemistry.
Martin L WilliamsFrom Medicinal Chemistry.
Craig S ClementsFrom Medicinal Chemistry.
Olga IlyichovaFrom Medicinal Chemistry.
Bradley C DoakFrom Medicinal Chemistry.
Patrick Genisselthe Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France.
Richard J Weaverthe Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France.
Laurent Vuillardthe Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France.
Michelle L HallsDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia and michelle.halls@monash.edu.
Christopher J H PorterDrug Delivery, Disposition and Dynamics, and chris.porter@monash.edu.ORCID 0000-0003-3474-7551
Martin J ScanlonFrom Medicinal Chemistry, martin.scanlon@monash.edu.ORCID 0000-0002-9230-7506
Institute of Medicinal Plant Development · CNServier (France) · FRDiscovery Institute · USIIE MSA · ZAKindeva Drug Delivery (United States) · USSystem Dynamics International (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peroxisome proliferator-activated receptor α (PPARα) is a transcriptional regulator of lipid metabolism. GW7647 is a potent PPARα agonist that must reach the nucleus to activate this receptor. In cells expressing human fatty acid-binding protein 1 (FABP1), GW7647 treatment increases FABP1's nuclear localization and potentiates GW7647-mediated PPARα activation; GW7647 is less effective in cells that do not express FABP1. To elucidate the underlying mechanism, here we substituted residues in FABP1 known to dictate lipid signaling by other intracellular lipid-binding proteins. Substitutions of Lys-20 and Lys-31 to Ala in the FABP1 helical cap affected neither its nuclear localization nor PPARα activation. In contrast, Ala substitution of Lys-57, Glu-77, and Lys-96, located in the loops adjacent to the ligand-binding portal region, abolished both FABP1 nuclear localization and GW7647-induced PPARα activation but had little effect on GW7647-FABP1 binding affinity. Using solution NMR spectroscopy, we determined the WT FABP1 structure and analyzed the dynamics in the apo and GW7647-bound structures of both the WT and the K57A/E77A/K96A triple mutant. We found that GW7647 binding causes little change in the FABP1 backbone, but solvent exposes several residues in the loops around the portal region, including Lys-57, Glu-77, and Lys-96. These residues also become more solvent-exposed upon binding of FABP1 with the endogenous PPARα agonist oleic acid. Together with previous observations, our findings suggest that GW7647 binding stabilizes a FABP1 conformation that promotes its interaction with PPARα. We conclude that full PPARα agonist activity of GW7647 requires FABP1-dependent transport and nuclear localization processes.

Indexed as

ButyratesFatty Acid-Binding ProteinsHumansLigandsModels, MolecularMutationPhenylurea CompoundsPPAR alphaProtein ConformationButyratesFABP1 protein, humanFatty Acid-Binding ProteinsGW 7647LigandsPhenylurea CompoundsPPAR alphadrug deliveryfatty acid–binding proteinGW7647nuclear magnetic resonance (NMR)nuclear receptorperoxisome proliferator-activated receptor (PPAR)PPARα agonistprotein structuretranscription factor

Identifiers

PMID30598509
PMCPMC6416440
OpenAlexW2906035266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.